Scarica l'app Stockscreener
3.36
3.70%
0.12
Dopo l'orario di chiusura:
3.36
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Savara Inc Borsa (SVRA) Ultime notizie
Savara Grants 150,000 Share Inducement Awards to New Employees | SVRA Stock News - StockTitan
Savara Announces New Employment Inducement Grant - Business Wire
Savara to Present Phase 3 Trial Results for Breakthrough aPAP Treatment at BTS Meeting | SVRA Stock News - StockTitan
Jennison Associates LLC Raises Stock Position in Savara Inc (NASDAQ:SVRA) - MarketBeat
Independent Director of Savara Picks Up 4.5% More Stock - Simply Wall St
Savara Inc. Reports Third-Quarter Financial Results and Announces Key Regulatory Milestones - MSN
Insider Buying Alert: Joseph Mccracken Acquires 20,000 Shares of Savara Inc (SVRA) - GuruFocus.com
Savara director Joseph McCracken acquires $59,071 in common stock - Investing.com India
Savara director Joseph McCracken acquires $59,071 in common stock By Investing.com - Investing.com Canada
Director David Ramsay Acquires 100,000 Shares of Savara Inc (SVR - GuruFocus.com
Savara Inc director David Ramsay buys $287,600 in common stock - Investing.com
Savara Inc director David Ramsay buys $287,600 in common stock By Investing.com - Investing.com UK
Savara (NASDAQ:SVRA) Shares Down 8.5%Time to Sell? - MarketBeat
Prudential Financial Inc's Strategic Acquisition of Savara Inc S - GuruFocus.com
What is HC Wainwright's Estimate for Savara FY2024 Earnings? - MarketBeat
Evercore ISI Reiterates In-Line Rating for Savara (NASDAQ:SVRA) - Defense World
Savara (NASDAQ:SVRA) Reaches New 1-Year Low on Analyst Downgrade - MarketBeat
SVRA stock touches 52-week low at $3.27 amid market challenges - Investing.com India
500: Something went wrong - Investing.com Canada
Evercore Downgrades Savara on Manufacturing Concerns for Lung Disease Drug Candidate - GuruFocus.com
Savara downgraded at Evercore on manufacturing concerns for lung disease candidate - Seeking Alpha
Savara (NASDAQ:SVRA) Shares Gap Down on Analyst Downgrade - MarketBeat
Savara (NASDAQ:SVRA) Price Target Lowered to $6.00 at HC Wainwright - MarketBeat
Savara (NASDAQ:SVRA) Earns "In-Line" Rating from Evercore ISI - MarketBeat
Savara (SVRA) to Present at Jefferies and Piper Sandler Healthcare Conferences | SVRA Stock News - StockTitan
Jennison Associates LLC's Strategic Acquisition of Savara Inc Sh - GuruFocus.com
Savara Reports Third Quarter 2024 Financial Results and Provides Business Update - Business Wire
Savara Inc (NASDAQ:SVRA) Receives $11.17 Average Price Target from Analysts - MarketBeat
Savara Inc. to Participate in Guggenheim Inaugural Healthcare Conference - MyChesCo
Wellington Management Group LLP's Strategic Acquisition in Savar - GuruFocus.com
SVRASavara Inc. Latest Stock News & Market Updates - StockTitan
Savara (NASDAQ:SVRA) Stock Price Down 5.1%Should You Sell? - MarketBeat
Savara to Present at the Guggenheim Inaugural Healthcare Innovation Conference - StockTitan
Savara Inc. Shines Spotlight on Rare Lung Disease in New TV Feature - MSN
Savara Inc. Rewards New Employees with Inducement Awards - MSN
Savara Announces the Rare Lung Disease, Autoimmune Pulmonary Alveolar Proteinosis (aPAP), is Highlighted on a New Episode of “The Balancing Act®” Airing on Lifetime® TV - Business Wire
Savara Inc (NASDAQ:SVRA) Receives Average Rating of "Buy" from Brokerages - MarketBeat
Savara Announces New Employment Inducement Grant | SVRA Stock News - StockTitan
Savara Inc (SVRA) deserves deeper analysis - US Post News
Ratio Review: Analyzing Savara Inc (SVRA)’s Price-to-Cash and Price-to-Free Cash Flow - The Dwinnex
Savara Inc (SVRA) Stock: 52-Week Performance Insights and Trading Volume - The InvestChronicle
Savara Inc. Launches Early Access Program for Rare Lung Disease Treatment - MSN
Savara maintains Overweight rating from Piper Sandler on bullish aPAP therapy prospects - Investing.com UK
Savara (NASDAQ:SVRA) Trading Down 3.4%Here's What Happened - MarketBeat
Cantaloupe, Inc. Executives Boost Confidence with Significant Stock Purchases - MyChesCo
Savara stock outlook steady as H.C. Wainwright highlights challenges in doctor engagement at CHEST meeting - Investing.com
Savara (NASDAQ:SVRA) Receives "Buy" Rating from HC Wainwright - MarketBeat
Should investors be concerned about Savara Inc (SVRA)? - US Post News
The growth track for Savara Inc (SVRA) has changed recently - SETE News
Stock Surge: Savara Inc (SVRA) Closes at 3.82, Marking a 0.26 Increase/Decrease - The Dwinnex
Marshall Wace LLP Has $1.23 Million Stake in Savara Inc (NASDAQ:SVRA) - MarketBeat
Algert Global LLC Boosts Stock Position in Savara Inc (NASDAQ:SVRA) - Defense World
Savara Inc. Grants Inducement Awards to New Employee - MSN
Savara Inc. Grants Inducement Awards to New Chief Commercial Officer - MSN
Piper Sandler keeps Overweight rating on Savara shares - Investing.com
1.89%
2.08%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):